1: Yamada S, Morine Y, Imura S, Ikemoto T, Saito Y, Shimizu M, Tsuneyama K,
Nishiyama M, Ishizawa S, Shimada M. Effect of daikenchuto (TU-100) on
carcinogenesis in non-alcoholic steatohepatitis. J Med Invest.
2023;70(1.2):66-73. doi: 10.2152/jmi.70.66. PMID: 37164745.
2: Takasu C, Miyazaki K, Yoshikawa K, Nishi M, Tokunaga T, Kashihara H,
Yoshimoto T, Ogawa H, Morine Y, Shimada M. Effect of TU-100 on Peyer's patches
in a bacterial translocation rat model. Ann Gastroenterol Surg. 2021 Apr
5;5(5):683-691. doi: 10.1002/ags3.12460. PMID: 34585053; PMCID: PMC8452476.
3: Chen S, Morine Y, Saito YU, Yamada S, Teraoku H, Ikemoto T, Shimada M. TU-100
Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor
Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis. Anticancer Res. 2023
May;43(5):1985-1992. doi: 10.21873/anticanres.16359. PMID: 37097685.
4: Takasu C, Yismaw WG, Kurita N, Yoshikawa K, Kashihara H, Kono T, Shimada M.
TU-100 exerts a protective effect against bacterial translocation by maintaining
the tight junction. Surg Today. 2017 Oct;47(10):1287-1294. doi:
10.1007/s00595-017-1518-6. Epub 2017 Apr 18. PMID: 28421347.
5: Ueno N, Hasebe T, Kaneko A, Yamamoto M, Fujiya M, Kohgo Y, Kono T, Wang CZ,
Yuan CS, Bissonnette M, Chang EB, Musch MW. TU-100 (Daikenchuto) and ginger
ameliorate anti-CD3 antibody induced T cell-mediated murine enteritis: microbe-
independent effects involving Akt and NF-κB suppression. PLoS One. 2014 May
23;9(5):e97456. doi: 10.1371/journal.pone.0097456. PMID: 24857966; PMCID:
PMC4032249.
6: Wada Y, Tokuda K, Morine Y, Okikawa S, Yamashita S, Ikemoto T, Imura S, Saito
Y, Yamada S, Shimada M. The inhibitory effect of TU-100 on hepatic stellate cell
activation in the tumor microenvironment. Oncotarget. 2020 Dec
8;11(49):4593-4604. doi: 10.18632/oncotarget.27835. PMID: 33346211; PMCID:
PMC7733620.
7: Hasebe T, Matsukawa J, Ringus D, Miyoshi J, Hart J, Kaneko A, Yamamoto M,
Kono T, Fujiya M, Kohgo Y, Wang CZ, Yuan CS, Bissonnette M, Musch MW, Chang EB.
Daikenchuto (TU-100) Suppresses Tumor Development in the Azoxymethane and
APCmin/+ Mouse Models of Experimental Colon Cancer. Phytother Res.
2017 Jan;31(1):90-99. doi: 10.1002/ptr.5735. Epub 2016 Oct 12. PMID: 27730672;
PMCID: PMC5590753.
8: Hasebe T, Ueno N, Musch MW, Nadimpalli A, Kaneko A, Kaifuchi N, Watanabe J,
Yamamoto M, Kono T, Inaba Y, Fujiya M, Kohgo Y, Chang EB. Daikenchuto (TU-100)
shapes gut microbiota architecture and increases the production of ginsenoside
metabolite compound K. Pharmacol Res Perspect. 2016 Feb 10;4(1):e00215. doi:
10.1002/prp2.215. PMID: 26977303; PMCID: PMC4777267.
9: Kono T, Omiya Y, Hira Y, Kaneko A, Chiba S, Suzuki T, Noguchi M, Watanabe T.
Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous
adrenomedullin in Crohn's disease rat model. J Gastroenterol. 2011
Oct;46(10):1187-96. doi: 10.1007/s00535-011-0438-2. Epub 2011 Aug 2. PMID:
21808981.
10: Nobutani K, Miyoshi J, Musch MW, Nishiyama M, Watanabe J, Kaneko A, Yamamoto
M, Yoshida M, Kono T, Jeong H, Chang EB. Daikenchuto (TU-100) alters murine
hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model:
effects of gender and withdrawal. Pharmacol Res Perspect. 2017 Oct;5(5):e00361.
doi: 10.1002/prp2.361. PMID: 28971602; PMCID: PMC5625165.